|
|
Post by harryx1 on Jun 20, 2018 15:03:23 GMT -5
|
|
|
|
Post by sla55 on Jun 20, 2018 15:05:17 GMT -5
WESTLAKE VILLAGE, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that it will host an invitation-only luncheon at Lotte New York Palace on Wednesday, June 27, 2018 for institutional investors and analysts, also accessible by live webcast (details below). This event will feature leading endocrinologist, Steven V. Edelman, MD, University of California - San Diego, who will discuss the current and novel approaches to treatment and management of diabetes in Type 1 and Type 2 patients.
Michael Castagna, Chief Executive Officer of MannKind Corporation, will provide a corporate overview followed by MannKind’s Chief Medical Officer, David Kendall, presenting the latest Afrezza data released at the American Diabetes Association’s 78th Scientific Sessions held June 22-26, 2018. Dr. Edelman and MannKind’s management team will be available to answer questions at the conclusion of the event.
Dr. Edelman is a Professor of Medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California at San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego and the Director of the Diabetes Care Clinic, VA Medical Center. Dr. Edelman has strong interests in education and patient advocacy. He is the founder and director of Taking Control of Your Diabetes (TCOYD), a not-for-profit organization with the goal of teaching and motivating patients in diabetes self-care. Dr. Edelman was recently named in US News and World Report amongst the top 1% of endocrinologists in the United States.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via email.
|
|
|
|
Post by sportsrancho on Jun 20, 2018 15:14:00 GMT -5
|
|
|
|
Post by sportsrancho on Jun 20, 2018 15:19:47 GMT -5
Nate...$MNKD Nothing left to do but :-) :-) :-) Kudos to everyone who has managed to tune-out Team2013 (and the rest of The Cult) along the way!
|
|
|
|
Post by tingtongtung on Jun 20, 2018 15:30:04 GMT -5
Nate...$MNKD Nothing left to do but :-) :-) :-) Kudos to everyone who has managed to tune-out Team2013 (and the rest of The Cult) along the way! So, I will ask the question.. What does it mean? They are asking for investment for funds? Please let this be the kickstart that MNKD (and we) need.. |
|
|
|
Post by cjm18 on Jun 20, 2018 15:37:30 GMT -5
How many analyst upgrades are in order?
|
|
|
|
Post by kite on Jun 20, 2018 15:41:27 GMT -5
I live in New York... Can I attend?? I registered just in case and received the following: "We have received your RSVP request for the KOL Luncheon on Rapid Acting Insulin for the Management of Diabetes, hosted by MannKind Corporation. We will send you a confirmation email closer to event date to confirm space available for you to attend. Thanks for your interest!" |
|
|
|
Post by mytakeonit on Jun 20, 2018 16:00:17 GMT -5
Hmmm ... maybe we will receive a kite report soon  |
|
|
|
Post by traderdennis on Jun 21, 2018 13:05:55 GMT -5
Nate...$MNKD Nothing left to do but :-) :-) :-) Kudos to everyone who has managed to tune-out Team2013 (and the rest of The Cult) along the way! So, I will ask the question.. What does it mean? They are asking for investment for funds? Please let this be the kickstart that MNKD (and we) need.. In the past a group of investors (Deerfield, Sabby) have lunch, sign an intent to purchase additional shares at an agreed upon discounted price from the current market price. Once they have inked a deal, even tho it is not announced to the general public, those investors can legally being to short the stock as a hedge for this agreement they just signed. MNKD announces the deal once all of the investorys have signed on, stock price goes down. The only question is how much wainright or maxim can pump the price before the offering is signed. The pumping to being during ADA, the shorting right after. |
|
|
|
Post by kite on Jun 27, 2018 9:07:58 GMT -5
I live in New York... Can I attend?? I registered just in case and received the following: "We have received your RSVP request for the KOL Luncheon on Rapid Acting Insulin for the Management of Diabetes, hosted by MannKind Corporation. We will send you a confirmation email closer to event date to confirm space available for you to attend. Thanks for your interest!" Did they get back to you with a confirmation, and are you attending? Yes and yes. Is anyone else attending? It would be great to meet up! |
|
|
|
Post by tarheelblue004 on Jun 27, 2018 9:10:50 GMT -5
|
|
|
|
Post by kite on Jun 27, 2018 9:14:43 GMT -5
I will do my best to take a lot of photos and will take meeting notes. |
|
|
|
Post by tarheelblue004 on Jun 27, 2018 9:15:30 GMT -5
thanks kite
|
|
|
|
Post by mytakeonit on Jun 27, 2018 12:55:03 GMT -5
I will do my best to take a lot of photos and will take meeting notes. kite - just make sure that it isn't done in crayon. |
|
|
|
Post by mnholdem on Jun 27, 2018 13:26:32 GMT -5
I listened to the most of the webcast - I had to skip part of it for a brief meeting with two of my managers - and Dr. Kendall made some comments that were very eye-opening.
The first trial patient who inhaled Afrezza did so twenty years ago. In all that time, with over 60 trials (which does not include another couple dozen preclinical studies) MannKind has only had six publications of the data related to their trial results. Six! David went on to state that MannKind will release its first publication on the STAT results in the 2nd week of July. I am assuming that since he used the word "first" that there will be more publications to follow, including clinical information from the late-breaking poster on significant reductions of hypoglycemic excursions and A1c levels.
IMO, this is a team that gets it. A pharmaceutical company must publish information about a drug if they expect it to be widely adopted. Endocrinologists and primary care physicians who deal with diabetes absolutely want what's best for their patients, but they are not about to prescribe a treatment that they simply do not understand or know too little about. I'm looking forward to what I hope will be the first of many clinical data publications and I hope it shows up in a major medical journal.
Dr. Kendall also mentioned that MannKind is currently preparing another trial that will be aimed at improving the Afrezza label. He did not provide specifics about trial endpoints, but Kendall did mention that they are planning to schedule the trial later this year and that the trial would be very short in duration.
It seems to me that this new executive team is focused on the critical steps needed in order to achieve industry-wide adoption of Afrezza.
 |
|
